Barclays Maintains an 'Underweight' on Boston Scientific (BSX); Potential Piece in Turnaround Story

Barclays maintains an 'Underweight' on Boston Scientific (NYSE: BSX) price target of $6.00.

Analyst, Adam Feinstein, feels that the upcoming FDA meetings of Circulatory System Devices Panel to discuss Cameron Health's subcutaneous ICD (S-ICD) System (on 4/26) is a positive for BSX and negative for Edward Lifesciences (NYSE: EW), since Heartware's (Nasdaq: HTWR) panel review is on 4/25 and EW will probably have to reschedule to May or June for review."

NOTE - Cameron is a company acquired by BSX. Cameron's S-ICD product has already been approved in Europe and has already been implanted into 1,000 patients overseas.

However, Barclays Feinstein still rates BSX at Underweight, citing pressures on the company's core CRM and stent products, but feels this is ultimately a turnaround story.

For an analyst ratings summary and ratings history on Boston Scientific click here. For more ratings news on Boston Scientific click here.

Shares of Boston Scientific closed at $6.04 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Mesoblast completes patient treatment in phase 3 back pain trial
• Powell Industries (POWL) PT Lowered to $235 at Cantor Fitzgerald
• UBS Reiterates Buy Rating on HF Sinclair (DINO)